Improvement in the renal prognosis in nephropathic cystinosis

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 10, 2011, Pages 2485-2491

  van Stralen, Karlijn J ^a   Emma, Francesco ^b   Jager, Kitty J ^a   Verrina, Enrico ^c   Schaefer, Franz ^d   Laube, Guido F ^e   Lewis, Malcolm A ^f   Levtchenko, Elena N ^g  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^f ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE;

ARTICLE; BODY HEIGHT; CHILD; CONTROLLED STUDY; CYSTINOSIS; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; HYPERTENSION; KIDNEY ALLOGRAFT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROPATHIC CYSTINOSIS; RENAL REPLACEMENT THERAPY; SCHOOL CHILD; SURVIVAL TIME;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CYSTINOSIS; DISEASE PROGRESSION; EUROPE; FEMALE; GRAFT SURVIVAL; GROWTH DISORDERS; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LOGISTIC MODELS; MALE; NEPHROTIC SYNDROME; PARATHYROID HORMONE; REGISTRIES; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 80053968071     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02000311     Document Type: Article

References (29)

1. Town M, Jean G, Cherqui S, Attard M, Forestier L, Whitmore SA, Callen DF, Gribouval O, Broyer M, Bates GP, van't Hoff W, Antignac C: A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nat Genet 18: 319-324, 1998
2. Cochat P, Cordier B, Lacôte C, Saïd MH: Cystinosis: Epidemiology in France. In: Cystinosis, edited by Broyer M, Paris, Elsevier, 1999, pp 28-35
3. Gahl WA, Thoene JG, Schneider JA: Cystinosis. N Engl J Med 347:111-121, 2002
4. Thoene JG, Oshima RG, Crawhall JC, Olson DL, Schneider JA: Cystinosis: Intracellular cystine depletion by aminothiols in vitro and in vivo. J Clin Invest 58: 180-189, 1976
5. Gahl WA, Reed GF, Thoene JG, Schulman JD, Rizzo WB, Jonas AJ, Denman DW, Schlesselman JJ, Corden BJ, Schneider JA: Cysteamine therapy for children with nephropathic cystinosis. N Engl J Med 316: 971-977, 1987
6. Markello TC, Bernardini IM, Gahl WA: Improved renal function in children with cystinosis treated with cysteamine. N Engl J Med 328: 1157-1162, 1993
7. van't Hoff WG, Gretz N: The treatment of cystinosis with cysteamine and phosphocysteamine in the United Kingdom and Eire. Pediatr Nephrol 9: 685-689, 1995
8. Greco M, Brugnara M, Zaffanello M, Taranta A, Pastore A, Emma F: Long-term outcome of nephropathic cystinosis: A 20-year singlecenter experience. Pediatr Nephrol 25: 2459-2467, 2010
9. Levtchenko EN, van Dael CM, de Graaf-Hess AC, Wilmer MJ, van den Heuvel LP, Monnens LA, Blom HJ: Strict cysteamine dose regimen is required to prevent nocturnal cystine accumulation in cystinosis. Pediatr Nephrol 21: 110-113, 2006
10. Tizard EJ, Verrina E, van Stralen KJ, Jager KJ: Progress with the European Society for Paediatric Nephrology (ESPN)/ERAEDTA Registry for children with established renal failure (ERF). Nephrol Dial Transplant 24: 2615-2617, 2009
11. ERA-EDTA Registry: ERA-EDTA Registry Annual Report 2007, Amsterdam, the Netherlands, Academic Medical Center, Department of Medical Informatics, 2009
12. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL: 2000 CDC Growth Charts for the United States: Methods and development. Vital Health Stat 11(246): 111-190, 2002
13. van Stralen KJ, Jager KJ, Schaefer F, Verrina E, Emma F: Suggested revision of the (NHBPEP) blood pressure standardization for growth retarded children. Pediatr Nephrol 26: 819-820, 2011
14. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents: The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114[2 Suppl 4th Report]: 555-576, 2004
15. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet 370: 1453-1457, 2007
16. van der Heijden BJ, van Dijk PC, Verrier-Jones K, Jager KJ, Briggs JD: Renal replacement therapy in children: Data from 12 registries in Europe. Pediatr Nephrol 19: 213-221, 2004
17. Ridgen S: Data from the ERA-EDTA Registry. In: Cystinosis, edited by Broyer M, Amsterdam, Elsevier, 1999, pp 20-27
18. Ged C, Jean G, Tete MJ, Broyer M, Kamoun P: Intra-leukocyte cystine in cystinosis treated with cysteamine. Ann Biol Clin 49: 482-486, 1991
19. Wilmer MJ, Kluijtmans LA, van der Velden TJ, Willems PH, Scheffer PG, Masereeuw R, Monnens LA, van den Heuvel LP, Levtchenko EN: Cysteamine restores glutathione redox status in cultured cystinotic proximal tubular epithelial cells. Biochim Biophys Acta 1812: 643-651, 2011
20. Laube GF, Shah V, Stewart VC, Hargreaves IP, Haq MR, Heales SJ, van't Hoff WG: Glutathione depletion and increased apoptosis rate in human cystinotic proximal tubular cells. Pediatr Nephrol 21: 503-509, 2006
21. Wilmer MJ, Emma F, Levtchenko EN: The pathogenesis of cystinosis: Mechanisms beyond cystine accumulation. Am J Physiol Renal Physiol 299: F905-F916, 2010
22. Levtchenko E, de Graaf-Hess A, Wilmer M, van den Heuvel L, Monnens L, Blom H: Altered status of glutathione and its metabolites in cystinotic cells. Nephrol Dial Transplant 20: 1828-1832, 2005
23. Mannucci L, Pastore A, Rizzo C, Piemonte F, Rizzoni G, Emma F: Impaired activity of the gamma-glutamyl cycle in nephropathic cystinosis fibroblasts. Pediatr Res 59: 332-335, 2006
24. Besouw M, Blom H, Tangerman A, de Graaf-Hess A, Levtchenko E: The origin of halitosis in cystinotic patients due to cysteamine treatment. Mol Genet Metab 91: 228-233, 2007
25. Dohil R, Newbury RO, Sellers ZM, Deutsch R, Schneider JA: The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine. J Pediatr 143: 224-230, 2003
26. Zhang GY, Spicer R, McTaggart S, Roy LP, Alexander SI: Outcomes in peadiatric renal transplant recipiets with cystinosis (1981-2008) [Abstract]. Transplantation 90: 1066, 2010
27. Wuhl E, Haffner D, Offner G, Broyer M, van't Hoff W, Mehls O: Long-term treatment with growth hormone in short children with nephropathic cystinosis. J Pediatr 138: 880- 87, 2001
28. Kimonis VE, Troendle J, Rose SR, Yang ML, Markello TC, Gahl WA: Effects of early cysteamine therapy on thyroid function and growth in nephropathic cystinosis. J Clin Endocrinol Metab 80: 3257-3261, 1995
29. Besouw M, Levtchenko E: Growth retardation in children with cystinosis. Minerva Pediatr 62: 307-314, 2010